Free Trial

Ligand Pharmaceuticals (LGND) Competitors

Ligand Pharmaceuticals logo
$114.38 +0.73 (+0.64%)
As of 07/3/2025 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LGND vs. ADMA, ANIP, RGEN, MDGL, HALO, IONS, ALKS, BCRX, FOLD, and CLDX

Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector.

Ligand Pharmaceuticals vs. Its Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Ligand Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$167.13M13.20-$4.03M-$7.12-16.07
ADMA Biologics$426.45M10.24$197.67M$0.8521.52

ADMA Biologics has a net margin of 45.01% compared to Ligand Pharmaceuticals' net margin of -73.07%. ADMA Biologics' return on equity of 47.16% beat Ligand Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals-73.07% -7.83% -6.92%
ADMA Biologics 45.01%47.16%30.51%

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ADMA Biologics had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for ADMA Biologics and 6 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.91 beat ADMA Biologics' score of 0.80 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADMA Biologics
8 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ligand Pharmaceuticals currently has a consensus price target of $146.14, suggesting a potential upside of 27.76%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 51.23%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Summary

ADMA Biologics beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGND vs. The Competition

MetricLigand PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.21B$2.91B$5.54B$9.05B
Dividend YieldN/A2.44%5.24%4.02%
P/E Ratio-16.0721.5627.4320.23
Price / Sales13.20281.76422.11118.64
Price / Cash71.3142.7336.8958.07
Price / Book2.607.518.045.67
Net Income-$4.03M-$55.05M$3.18B$249.13M
7 Day Performance0.21%4.61%2.89%3.28%
1 Month Performance9.80%4.72%3.70%5.56%
1 Year Performance35.58%5.92%36.15%21.12%

Ligand Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGND
Ligand Pharmaceuticals
4.7765 of 5 stars
$114.39
+0.6%
$146.14
+27.8%
+38.3%$2.21B$167.13M-16.0780Positive News
ADMA
ADMA Biologics
4.1158 of 5 stars
$18.21
+0.3%
$27.67
+51.9%
+63.2%$4.34B$426.45M32.43530
ANIP
ANI Pharmaceuticals
3.7185 of 5 stars
$65.25
-0.4%
$80.13
+22.8%
+7.4%$1.42B$614.38M14.62600
RGEN
Repligen
4.8154 of 5 stars
$124.38
+0.7%
$172.83
+39.0%
+5.5%$6.94B$634.44M77.711,778Positive News
MDGL
Madrigal Pharmaceuticals
4.096 of 5 stars
$302.64
+0.6%
$420.63
+39.0%
+9.9%$6.68B$180.13M0.0090
HALO
Halozyme Therapeutics
4.8528 of 5 stars
$52.02
-0.4%
$61.90
+19.0%
+3.9%$6.43B$1.02B12.31390High Trading Volume
IONS
Ionis Pharmaceuticals
4.6679 of 5 stars
$39.51
-0.7%
$57.88
+46.5%
-5.7%$6.33B$705M0.001,069News Coverage
Analyst Upgrade
ALKS
Alkermes
4.9369 of 5 stars
$28.61
-0.7%
$40.00
+39.8%
+18.7%$4.75B$1.56B12.751,800Positive News
Analyst Revision
BCRX
BioCryst Pharmaceuticals
4.4751 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+39.5%$1.96B$450.71M0.00530Analyst Forecast
Analyst Revision
FOLD
Amicus Therapeutics
3.708 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-37.3%$1.83B$528.29M197.67480
CLDX
Celldex Therapeutics
3.1078 of 5 stars
$20.35
+0.3%
$50.11
+146.2%
-38.8%$1.35B$7.02M0.00150

Related Companies and Tools


This page (NASDAQ:LGND) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners